araag2/HINT huggingface dataset:
Clinical trial NCT01414855 (phase 2, status: completed)
Conditions: lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥18 years of age

          -  Previously untreated cluster of differentiation antigen 20 (CD20)-positive diffuse
             large B-cell lymphoma

          -  Ann Arbour Stage III/IV and bulky II (mass >10 cm)

          -  At least one bi-dimensionally measurable lesion defined as >1.5 cm in its largest
             dimension by CT scan

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Left ventricular ejection fraction ≥50%

          -  Adequate hematologic function

        Exclusion Criteria:

          -  Transformed lymphoma (follicular IIIB) if previously treated with chemotherapy or
             immunotherapy

          -  Prior therapy for diffuse large B-cell lymphoma except for nodal biopsy or local
             irradiation

          -  Central nervous system (CNS) lymphoma, primary mediastinal large cell lymphoma,
             primary cutaneous lymphoma, primary effusion lymphoma

          -  Patients who received cytotoxic drugs or rituximab as part of their treatment for
             another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody

          -  Chemotherapy or other investigational therapy within 28 days prior to the start of
             Cycle 1

          -  Contraindication to any of the individual components of CHOP, including prior receipt
             of anthracyclines

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy

          -  History of other malignancy, except for curatively treated basal or squamous cell
             carcinoma or melanoma of the skin or in situ carcinoma of the cervix, or malignancy
             treated with or without curative intent and in remission without treatment for ≥2
             years prior to enrolment

          -  Positive for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or human
             T-cell leukemia virus (HTLV-1) infection

          -  Pregnant or lactating women
Clinical trial NCT00515255 (phase 2, status: terminated)
Conditions: obsessive compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: minocycline
SMILES: [H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
Reason stopped: 
    recruitment goal of 20 not met
  
Eligibility criteria:

        Inclusion Criteria:

          -  Meets DSM-IV criteria for Obsessive Compulsive Disorder.

          -  CY-BOCS score of greater or equal to 16 at screening.

          -  NIMH Global OC Scale score of 7 or higher at screening.

        Exclusion Criteria:

          -  Patients planning to commence cognitive behaviour therapy during the period of the
             study or those who have begun cognitive behaviour therapy within 8 weeks prior to
             enrolment.

          -  Autistic Disorder or Pervasive Developmental Disorder.

          -  Moderate or severe mental retardation.

          -  Severe renal insufficiency.

        Other protocol-defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT00490776 (phase 2/phase 3, status: completed)
Conditions: cutaneous t-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lbh589
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Eligibility criteria:

        Inclusion criteria:

          1. Written informed consent obtained prior to any screening procedures

          2. Age greater than or equal to 18 years old

          3. Patients with biopsy-confirmed stages IB-IVA mycosis fungoides or Sézary syndrome.
             Patients with SS who have bone marrow involvement are also eligible. Patients with
             transformed CTCL are eligible.

          4. Patients must have been treated with an HDAC inhibitor given for the treatment of
             CTCL. Patients must have had disease progression on or following treatment with an
             HDAC inhibitor. Patients are also eligible if they had an inadequate response to an
             HDAC inhibitor defined as stable disease as the best response after at least 3 months
             of therapy. Patients previously treated with an HDAC inhibitor are also eligible if
             they experienced intolerance due to adverse events.

        Exclusion criteria:

          1. Patients with a history of visceral disease including CNS involvement (i.e. stage IVB
             CTCL). Note, patients who have SS with bone marrow involvement are eligible.

          2. Impaired cardiac function

          3. Concomitant use of drugs with a risk of causing torsades de pointes

          4. Patients who have received chemotherapy or any investigational drug or undergone major
             surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side
             effects of such therapy

          5. Less than 3 months since prior electron beam therapy

          6. Women who are pregnant or breast feeding, or women of childbearing potential (WOCBP)
             not willing to use a double method of contraception during the study and 3 months
             after the end of treatment.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00185380 (phase 2, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: levonorgestrel ius (bay86-5028, g04209b), levonorgestrel ius (bay86-5028, g04209c), levonorgestrel ius (mirena, bay86-5028)
SMILES: [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Women with or without children and good general health and in need of contraception.

          -  Regular menstrual cycle without hormonal contraceptives.

        Exclusion Criteria:

          -  Pregnant or lactating.

          -  Last delivery or abortion less than 12 weeks ago.

          -  Previous pregnancies outside the womb.

          -  Previous pelvic infections.

          -  Abnormal bleeding.

          -  Abnormal uterine cavity.

          -  Climacteric signs.

          -  Genital cancer.

          -  Liver diseases.

          -  Alcoholism or drug abuse.
Clinical trial NCT01189032 (phase 2, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: de-089 ophthalmic solution, de-089 ophthalmic solution, placebo ophthalmic solution
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Those who show:

               -  Keratoconjunctival disorder confirmed with vital dye staining

               -  Abnormal Schirmer score results

        Exclusion Criteria:

          -  Eye disease that needs therapy other than that for dry eye

          -  Those who need to wear contact lenses during the clinical study
Clinical trial NCT00305448 (phase 2, status: completed)
Conditions: advanced breast cancer, metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: fulvestrant, fulvestrant
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H], [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Breast Cancer has continued to grow after having received treatment with an
             anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor

          -  Requiring hormonal treatment

          -  Postmenopausal women defined as a woman who has stopped having menstrual periods

        Exclusion Criteria:

          -  Treatment with more than one previous regimen of systemic anticancer therapy other
             than endocrine therapy for advanced breast cancer

          -  Treatment with more than one previous regimen of endocrine therapy for advanced breast
             cancer

          -  An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures
Clinical trial NCT00563563 (phase 2, status: completed)
Conditions: nicotine dependence, overweight, obesity
ICD codes: F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228, E66.3, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: nb32
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          1. Female and male subjects must be 18 to 65 years of age;

          2. Have body mass index (BMI) greater than or equal to 27 and less than or equal to
             45kg/m2;

          3. Have smoked an average of at least 10 cigarettes/day in the preceding year, with < 3
             month total abstinence period;

          4. Self-reported level of motivation to stop smoking ≥ 7, on a scale of 1-to-10;

          5. At least moderately concerned about gaining weight after quitting smoking

          6. Women of child-bearing potential, must be non-lactating and agree to use effective
             contraception throughout the study period and 30 days after discontinuation of study
             drug;

          7. Able to comply with all required study procedures and schedule;

          8. Able to speak and read English;

          9. Willing and able to give written informed consent.

        Key Exclusion Criteria:

          1. Obesity of known endocrine origin

          2. Serious medical condition

          3. History of drug or alcohol abuse or dependence

          4. Use of excluded concomitant medications

          5. History of surgical or device (e.g. gastric banding) intervention for obesity;

          6. History or predisposition to seizures

          7. Pregnant or breast-feeding women or planning to become pregnant during the study
             period or within 30 days of discontinuing study drug;

          8. Planned surgical procedure that can impact the conduct of the study;

          9. Use of investigational drug, device or procedure within 30 days prior to Screening;

         10. Participation in any previous clinical trial conducted by Orexigen Therapeutics;

         11. Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in the study.
Clinical trial NCT00626106 (phase 2, status: completed)
Conditions: breast cancer, breast tumors, metastatic cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant, amg 479 or placebo administered with either exemestane or fulvestrant
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed carcinoma of the breast with locally
             advanced or metastatic disease

          -  Confirmation of hormone receptor (HR) positive disease status

          -  Amenable to receive endocrine therapy

          -  Disease progression while receiving prior endocrine therapy for locally advanced or
             metastatic breast cancer

          -  Postmenopausal woman ≥ 18 years old

        Exclusion Criteria:

          -  HR-unknown or HR-negative disease

          -  Not amenable to endocrine therapy

          -  Central nervous system metastasis
Clinical trial NCT00068393 (phase 2, status: completed)
Conditions: metastatic renal cell carcinoma, renal cell carcinoma with sarcomatoid features
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: doxorubicin, gemcitabine, g-csf (granulocyte-colony stimulating factor), neulasta
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Histologically confirmed renal cell carcinoma

               -  Features must be of sarcomatoid histology

               -  Locally recurrent or metastatic disease not amenable to resection

          -  Measurable disease

          -  Must have a prior nephrectomy provided all other eligibility criteria are met, and
             adequately recovered from any recent surgery

          -  At least 4 weeks since prior radiotherapy and recovered

          -  ECOG performance status of 0-1

          -  WBC greater than 3,000/mm^3 or absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  Bilirubin less than 1.5 mg/dL

          -  Aspartate aminotransferase (AST) less than 2 times upper limit of normal

          -  Creatinine no greater than 2.0 mg/dL

          -  LVEF at least lower limit of normal by MUGA

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Other prior malignancy allowed provided patient was curatively treated and has been
             disease free from that cancer

          -  Age of 18 and over

          -  Diagnostic material from the kidney or metastatic site biopsy available for central
             pathologic review

        EXCLUSION CRITERIA:

          -  Prior treatment for advanced disease

          -  Previously irradiated lesions as the sole site of disease for patients with prior
             radiation therapy

          -  Concurrent local radiotherapy for pain control or for life-threatening situations

          -  Myocardial infarction within the past year

          -  Congestive heart failure within the past year

          -  Significant ischemic or valvular heart disease within the past year

          -  Prior or concurrent brain metastases

          -  Concurrent serious medical illness that would preclude study treatment

          -  Active infection that would preclude study treatment

          -  Pregnant or nursing
Clinical trial NCT00372775 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with radiologically proven brain metastases secondary to non-small cell lung
             cancer

          -  Received previous whole brain radiation therapy and none, 1 or 2 prior systemic
             therapy for the treatment of advanced/metastatic non-small cell lung cancer

        Exclusion Criteria:

          -  Patients with brainstem lesions, spinal cord compression. carcinomatous meningitis, or
             leptomeningeal disease.

          -  Brain metastases >4 cm in any linear direction

          -  Intracranial or intratumoral hemorrhage
Clinical trial NCT01524497 (phase 2/phase 3, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: trazodone, placebo
SMILES: ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age between 18 and 65, males and females, outpatients or inpatients;

          2. Single episode or recurrent depression according to DSM-IV (Version 4) criteria;

          3. Scores > 18 on 17-item HAM-D at screening and baseline visits with a decrease not
             exceeding 20% between the two visits;

          4. Symptoms of depression for at least 1 month;

          5. Patients or their dependents/guardians providing signed informed consent forms.

        Exclusion Criteria:

          1. Serious suicide attempts (≥ 3 on item 3 'Suicide' of HAMD);

          2. Depressive episode, with psychotic symptoms;

          3. Refractory depression;

          4. Depressive episode secondary to other mental or physical disorders;

          5. Bipolar disorder;

          6. Significant reduction in body weight and malnutrition induced by major depression;

          7. Serious or unstable heart, hepatic, renal, endocrine and hematologic disease or
             malignant tumors;
Clinical trial NCT01649297 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, placebo, placebo, placebo, placebo, empagliflozin (low dose qd), placebo, placebo, placebo, placebo, placebo, placebo, placebo, placebo, placebo, placebo, empagliflozin (high dose qd), empagliflozin (high dose bid), placebo, empagliflozin (low dose bid)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion criteria:

          1. confirmed diagnosis of T2DM

          2. Glycated hemoglobin (HbA1c) >=7.0 and <=10/0% at Visit 1

          3. Metformin therapy (at least 1500 mg/day, BID)

          4. age>=18 at Visit 1

          5. body mass index <=45 kg/m2

        Exclusion criteria:

          1. estimated creatinine clearance rate (eCCr) <60 ml/min (Cockcroft-Gault formula)
             screening and/or run-in

          2. a confirmed glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during
             placebo run-in
Clinical trial NCT00119678 (phase 2, status: completed)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: abatacept, placebo, prednisone, abatacept
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O
Eligibility criteria:

        Inclusion Criteria:

          -  participants must be diagnosed with SLE and be experiencing an active lupus flare in
             at least one of three organ systems: skin (discoid lesions), inflammation of the
             lining of the heart (pericarditis), or inflammation of the lining of the lung
             (pleuritis/pleurisy); or inflammation of more than 4 joints within 14 days of a
             screening visit (arthritis)

          -  Stable dose of prednisone (<30mg) for at least one month

        Exclusion Criteria:

          -  participants experiencing an active lupus flare in the kidney or central nervous
             systems

          -  Treatment with a stable dose of azathioprine, mycophenolate mofetil,
             hydroxychloroquine, chloroquine, or methotrexate for less than three months prior to
             the study

          -  participants with active viral or bacterial infections

          -  participants with any other autoimmune disease as a main diagnosis

          -  Prior treatment with rituximab
Clinical trial NCT00071006 (phase 2, status: completed)
Conditions: acute myeloid leukemia (aml), myelodysplastic syndrome
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: ag-013736 (axitinib)
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Poor prognosis AML or MDS

          -  Histological confirmation of diagnosis

          -  White blood cell count less than or equal to 30,000/mm3

          -  Adequate hepatic and renal function documented within 14 days prior to registration

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  No evidence of preexisting uncontrolled hypertension

          -  Not a suitable candidate for chemotherapy

          -  No prior systemic chemotherapy treatment for AML or MDS or treatment with an
             anti-angiogenesis agent

        Exclusion Criteria:

          -  Patients must not have exclusion criteria.

          -  Candidate for chemotherapy

          -  Patients with AML M3 (acute promyelocytic leukemia)

          -  Conditions that might confound the evaluation of safety or efficacy or increase
             patient risk.
Clinical trial NCT00495326 (phase 2/phase 3, status: completed)
Conditions: tuberculosis, aids, hiv infections
ICD codes: A18.39, P37.0, Z22.7, A15.0, A15.7, A15.8, A15.9, Z21
Drugs: nevirapine based therapy, efavirenz based therapy, rifampicin (rmp) ethambutol (e) isoniazid (h) pyrazinamid (z)
SMILES: CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, NC(=O)C1=NC=CN=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Person HIV infected

          -  Aged of 18 years or more

          -  Signed informed consent

          -  New case of tuberculosis: patient who never received TB treatment or for less than 1
             month

          -  Patients receiving rifampicin based TB regimen since 4 to 6 weeks

          -  CD4 cell count < 250 cell/mm3 in the 4 weeks following the TB diagnosis

          -  Naïve of HAART

          -  For women of childbearing age, to have a negative plasmatic test for pregnancy and to
             accept to take a contraception or declare no wish of pregnancy in the coming year.

        Exclusion Criteria:

          -  To have a positive plasmatic test for pregnancy

          -  Karnofsky score <60%

          -  ALAT > 4N (Hepatitis grade 3 or 4)

          -  Ongoing psychiatric pathology

          -  Refuse to participate in the study

        Amendment :

          -  bilirubin > grade 3

          -  any grade 4 clinical sign or biological result at time of inclusion